Your session is about to expire
← Back to Search
HLX23 for Solid Tumors
Study Summary
The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.
- Advanced Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many healthcare institutions in the U.S. are currently participating in this clinical experiment?
"This experiment is presently enlisting participants from 6 distinct sites, including those based in Fairway, LA and Orange City. To mitigate the burden of travel associated with taking part in this trial, it may be prudent to select the closest location available."
Has Health and Human Services sanctioned HLX23 for use?
"As this is only a Phase 1 trial, with scant evidence of safety and efficacy, our team at Power has given HLX23 a score of 1 out of 3."
What is the aggregate figure of study participants enrolled in this experiment?
"Affirmative. Clinicaltrials.gov reflects that this research endeavour, which was initially published on July 18th 2022, is actively recruiting participants. In total, 30 people need to be recruited from 6 distinct sites."
What tangible results are anticipated from this trial?
"As per Shanghai Henlius Biotech, the primary aim of this trial – which will span 21 days - is to assess Dose Limiting Toxicity (DLT). Additionally, secondary outcomes such as Disease Control Rate (DCR), Pharmacodynamic(PD) and Overall Response Rate (ORR) shall undergo evaluation."
Are there any participants being accepted into this research endeavor currently?
"Affirmative. Information on clinicaltrials.gov reveals that this medical study, which was initially posted on July 18th 2022, is actively seeking participants. Approximately 30 patients must be enrolled from 6 different research centres."
Share this study with friends
Copy Link
Messenger